Latin America Pharmaceuticals and Healthcare Report Q2 2017
|出版日期||內容資訊||英文 35 Pages
|南美的醫藥品、醫療產業 (季度更新) Latin America Pharmaceuticals and Healthcare Report Q2 2017|
|出版日期: 2017年04月26日||內容資訊: 英文 35 Pages||
本報告提供南美的到醫藥品、醫療產業調查分析，到2025年的10年預測為焦點，產業分析，產業預測，產業風險/利潤指數 (RRI) 、市場概要，產業趨勢，各地區的概要等系統性資訊。
BMI View: The deteriorating political and economic outlook in Latin America is increasing the risks to multinational drugmakers' regional growth. For example, the increasing likelihood of a sovereign default in Venezuela will degrade the country's operating environment and impact multinational drugmakers' regional performance. NAFTA renegotiation also poses downside risks for the Mexican pharmaceutical sector with the potential for prolonged weakness in the Mexican peso, protectionist trade measures and restricted foreign direct investment. Nonetheless, government commitment to healthcare in Latin America remains a positive for long-term prospects, with the expansion of public medical services to provide significant commercial opportunities.
The Americas region will remain characterised by highly divergent levels of attractiveness for innovative pharmaceutical firms. While North America presents considerable opportunities for the commercialisation of pharmaceuticals, it is vital that companies appreciate the varying levels of investment risks and rewards that are present in the emerging markets of Latin America. BMI's Innovative Pharmaceuticals Risk/Reward Index tool, which provides a globally comparative and numerically based assessment of a market's attractiveness for companies looking to launch a high-value drug, was established to address this.